Coherus Oncology, Inc.
CHRS
$1.13
-$0.04-3.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -11.58% | -371.55% | 16.79% | -112.56% |
| Total Depreciation and Amortization | -- | 1.26% | -33.31% | 30.50% | -21.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -3.76% | 124.58% | 411.73% | 98.00% |
| Change in Net Operating Assets | -- | -80.09% | 188.64% | -182.85% | 752.70% |
| Cash from Operations | -- | -190.28% | 146.13% | -203.82% | 227.73% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -3,126.20% | -222.07% | -98.39% | -86.36% |
| Cash from Investing | -- | -3,126.20% | -222.07% | -98.39% | -86.36% |
| Total Debt Issued | -- | -- | 100.00% | -100.38% | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -58.00% |
| Repurchase of Common Stock | -- | -2,540.00% | 0.00% | 99.42% | -129.66% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -100.04% | 29,036.00% |
| Cash from Financing | -- | -214.29% | 238.32% | 99.91% | -21,286.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -254.00% | 145.83% | 38.59% | -164.08% |